

**Regd. Office :**

'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

BSE Limited 1 <sup>st</sup> Floor, P.J. Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: March 8, 2017	
Re.: Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated March 8, 2017, titled Zydus Cadila receives final approval from the USFDA for Tizanidine Hydrochloride Capsules.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, Cadila Healthcare Limited



Open H. Shah  
Company Secretary



Encl.: As above

## **Zydus Cadila receives final approval from the USFDA for Tizanidine Hydrochloride Capsules**

*Ahmedabad, March 8, 2017*

Cadila Healthcare Limited has received final approval from the USFDA to market Tizanidine Hydrochloride Capsules, USP in strengths of 2mg, 4mg and 6mg. The drug, which is a muscle relaxant, will be produced at the SEZ facility located at Ahmedabad. The estimated sales for Tizanidine Hydrochloride Capsules is \$ 58.6 million as per IMS Jan 2017.

The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*